Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 11/20 | 0.36 |
| ▸ | PDE1A | P54750 | 10/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 9/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.32 |
| ▸ | USP1 | O94782 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922433 | 0.93 | PIK3CA (0.36) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4919219 | 0.87 | HTT (0.36) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4921479 | 0.87 | PIK3CA (0.35) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2658389 | 0.87 | GRM1 (0.38) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2656785 | 0.85 | PIK3CA (0.37) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2660637 | 0.83 | LMNA (0.38) | SMN1; SMN2LMNAPARP1HTTPARP2 | |
| SCHEMBL2660334 | 0.83 | PIK3CA (0.39) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2660720 | 0.82 | GABRG2 (0.35) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2655626 | 0.82 | BRD9 (0.43) | TP53MAPTLMNAPARP1HTT | |
| SCHEMBL2660780 | 0.82 | GABRG2 (0.42) | SMN1; SMN2LMNAPARP1HTTPARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | NPC1 3293/4885TP53 1103/4885MAPT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.